Chemotherapy-Induced Myelosuppression in SCLC

UNC Lineberger Comprehensive Cancer Center
Avatar

Myelopreservation With the CDK4/6i Trilaciclib in Patients With SCLC Receiving 1L Chemotherapy

By UNC Lineberger Comprehensive Cancer Center FEATURING Jared Weiss
By UNC Lineberger Comprehensive Cancer Center FEATURING Jared Weiss
497 views
September 2, 2021
Comments 0
Login to view comments. Click here to Login
22:07

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression in E…

Jerome Goldschmidt

513 views
15:31

Importance of Addressing Myelosuppression in Chemotherapy Patients

Edgardo Santos​

184 views
15:30

Small Cell Lung Cancer: A Brief Review of the Treatment Landscape

Dana-Farber Cancer Institute

J. Sands

611 views
20:11

Myelosuppression in ES-SCLC Therapy

Maen Hussein

242 views
28:56

Nebraska Oncology Society 2022 SCLC Management Updates

Nebraska Oncology Society

T. Leal

179 views
27:09

Treatment Landscape of SCLC

Edgardo Santos​

189 views
22:38

Trilaciclib and the Economic Value of Multilineage Myeloprotection F…

Ivo Abraham

640 views
04:05

ASCO 2022 on KEYVIBE-008: Randomized, Phase 3 Study of 1L Vibostolim…

ASCO 2022 Conference Coverage

J. Sands

510 views
15:49

ASCO 2022 on Stereotactic Radiosurgery vs. WBRT in SCLC and Intracra…

ASCO 2022 Conference Coverage

K. Gaebe

431 views
14:23

ASCO 2022 Impact of Trilaciclib on Multilineage Chemo-Induced Myelos…

ASCO 2022 Conference Coverage

J. Goldschmidt

93 views
07:03

ASCO 2022 on Phase 3 ATLANTIS Trial: Analysis of Patients With Relap…

ASCO 2022 Conference Coverage

A. Navarro

253 views
25

Lecture Summary - ASCO 2022 on KEYVIBE-008: Randomized, Phase 3 Stud…

ASCO 2022 Conference Coverage

J. Sands

43 views
01:01

Lecture Summary - ASCO 2022 on Stereotactic Radiosurgery vs. WBRT in…

ASCO 2022 Conference Coverage

K. Gaebe

47 views
52

Lecture Summary - ASCO 2022 Analysis of Patients With Relapsed SCLC …

ASCO 2022 Conference Coverage

A. Navarro

23 views